Yazar "Sahin, Handan Haydaroglu" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    Gene Polymorphisms and Febrile Neutropenia in Acute Leukemia-No Association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 Are Associated with the Disease in Turkish Patients: A Preliminary Study
    (Mary Ann Liebert, Inc, 2014) Pehlivan, Mustafa; Sahin, Handan Haydaroglu; Ozdilli, Kursat; Onay, Huseyin; Ozcan, Ali; Özkınay, Ferda; Pehlivan, Sacide
    Aims: The aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy. Methods: The study included 60 AL patients hospitalized between the period of July 2001 and August 2006. Polymorphisms for the genes ACE(I/D), CCR-5, IL-1RA, MBL-2, TLR-4, and IL-4 were typed by polymerase chain reaction (PCR) and/or PCR-restriction fragment length polymerase. Genotype frequencies for these genes were compared in the patient and control groups. The relationships between the genotypes and the body distribution of infections, pathogens, the duration of neutropenia, and febrile episodes in AL patients were evaluated. Results: No significant differences in either the genotype distribution or the allelic frequencies of TLR-4, IL-4, CCR-5, IL-1RN GPs were observed between patients and healthy controls. The AB/BB genotype (53.3%) in the MBL-2 gene was found to be significantly higher in the AL patients compared with control groups. There were correlations between the presence of MBL-2, TLR-4, and ACE polymorphisms and clinical parameters due to FN. Overall, bacteremia was more common in MBL BB and ACE DD. Gram-positive bacteremia was more common in ACE for ID versus DD genotype. Gram-negative bacteremia was more common for both the MBL-2 AB/BB genotype and TLR-4 AG genotype. Median durations of febrile episodes were significantly shorter in ACE DD and MBL AB/BB. Conclusion: Although TLR-4, ACE, and MBL-2 GPs have been extensively investigated in different clinical pictures, this is the first study to evaluate the role of these polymorphisms in the genetic etiopathogenesis of FN in patients with ALs. As a conclusion, TLR-4, ACE, and MBL-2 genes might play roles in the genetic etiopathogenesis of FN in patients with ALs.
  • Küçük Resim Yok
    Öğe
    Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG)
    (Pergamon-Elsevier Science Ltd, 2020) Soyer, Nur; Gunduz, Mehmet; Tekgunduz, Emre; Deveci, Burak; Ozdogu, Hakan; Sahin, Handan Haydaroglu; Topcuoglu, Pervin
    Hepatic sinusoidal obstruction syndrome (HSOS) is a potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively evaluated the incidence, risk factors, treatment and survival for HSOS after allo-HSCT in Turkey. We also reported our experience of defibrotide (DF) for HSOS prophylaxis in high-risk (HR) patients. Across Turkey, 1153 patients from 10 centers were enrolled in the study. We evaluated the medical records of patients who were treated with allo-SCT between January 2012 and December 2015. The study included 1153 patients (687 males/466 females) with median age of 38 (15 - 71) years. The incidence of HSOS was 7.5 % (n = 86). The incidences of HSOS in the HR/DF +, HR/DF- and standard risk (SR) group were 8%, 66.7 % and 6.2 %, respectively. The rate of HSOS development was not statistically different between HR/DF + and SR group (p = 0.237). HSOS prophylaxis (defibrotide) was significantly decreased HSOS-related mortality (p = 0.004). The incidence of HSOS was found similar to literature in this large Turkish cohort. Defibrotide prophylaxis appears to be associated with low incidence of HSOS development and reduced HSOS-related mortality. Although these results are promising, future studies are needed to support the efficacy of defibrotide prophylaxis in patients with risk of HSOS.
  • Küçük Resim Yok
    Öğe
    Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic transplantation: Retrospective multicenter study of Turkish hematology research and education group (THREG), updated data
    (Nature Publishing Group, 2019) Soyer, Nur; Gunduz, Mehmet; Tekgunduz, Emre; Deveci, Burak; Ozdogu, Hakan; Sahin, Handan Haydaroglu; Turak, Esra Ermis; Okay, Mufide; Kuku, Irfan; Hindilerden, Ipek Yonal; Topcuoglu, Pervin; Altuntas, Feviz; Karadogan, Ihsan; Pehlivan, Mustafa; Unal, Ali; Goker, Hakan; Erkurt, Mehmet Ali; Besisik, Sevgi Kalayoglu; Vural, Filiz
  • Küçük Resim Yok
    Öğe
    Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
    (Galenos Yayincilik, 2013) Sahin, Fahri; Saydam, Güray; Comert, Melda; Uz, Burak; Yavuz, Akif Selim; Turan, Esra; Yonal, Ipek; Atay, Hilmi; Keltikli, Engin; Turgut, Mehmet; Pehlivan, Mustafa; Akay, Meltem Olga; Gurkan, Emel; Paydas, Semra; Kahraman, Selda; Demirkan, Fatih; Kirkizlar, Onur; Akpinar, Seval; Pamuk, Gulsum Emel; Demir, Muzaffer; Ozbas, Hasan Mucahit; Sonmez, Mehmet; Gulturk, Mine; Salihoglu, Ayse; Eskazan, Ahmet Emre; Ar, Cem; Sahin, Handan Haydaroglu; Ongoren, Seniz; Baslar, Zafer; Aydin, Yildiz; Yenere, Mustafa Nuri; Tuzuner, Nukhet; Ferhanoglu, Burhan; Haznedaroglu, Ibrahim C.; Ilhan, Osman; Soysal, Teoman
    Objective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices. Materials and Methods: In this article, we have evaluated 1133 patients' results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs. Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment. Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.
  • Küçük Resim Yok
    Öğe
    Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment
    (Springer, 2013) Selvi, Nur; Kaymaz, Burcin Tezcanli; Sahin, Handan Haydaroglu; Pehlivan, Mustafa; Aktan, Cagdas; Dalmizrak, Aysegul; Inalpolat, Ezgi; Kosova, Buket; Yilmaz, Mehmet; Okan, Vahap; Saydam, Güray
    The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.
  • Küçük Resim Yok
    Öğe
    Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment
    (Springer, 2013) Selvi, Nur; Kaymaz, Burcin Tezcanli; Sahin, Handan Haydaroglu; Pehlivan, Mustafa; Aktan, Cagdas; Dalmizrak, Aysegul; Inalpolat, Ezgi; Kosova, Buket; Yilmaz, Mehmet; Okan, Vahap; Saydam, Güray
    The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.